{"id":49214,"date":"2022-10-05T21:01:38","date_gmt":"2022-10-05T19:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/"},"modified":"2022-10-05T21:01:38","modified_gmt":"2022-10-05T19:01:38","slug":"oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/","title":{"rendered":"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5656272\/oral-biologics-and-biosimilars-global-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=nbptq4&amp;utm_campaign=1758645+-+Oral+Biologics+%26+Biosimilars+Global+Market+Report+2022%3A+Rising+Prevalence+of+Chronic+Diseases+Such+as+Arthritis%2C+Asthma%2C+and+Cancer+Driving+Growth&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Oral Biologics &amp; Biosimilars Global Market Report 2022&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe global oral biologics &amp; biosimilars market is expected to grow from $4.24 billion in 2021 to $5.24 billion in 2022 at a compound annual growth rate (CAGR) of 23.4%. The oral biologics &amp; biosimilars market is expected to grow to $9.44 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%.\n<\/p>\n<p>\nNorth America was the largest region in the oral biologics and biosimilar drugs market in 2021. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.\n<\/p>\n<p>\nThe rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the growth of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases.\n<\/p>\n<p>\nBiologics stimulate the immune system&#8217;s attack on cancer cells, aiding the body&#8217;s natural defenses in getting rid of the disease-causing cells. According to a United Nations article, a US-based intergovernmental organization, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. It is anticipated that chronic disease will account for nearly 60% of all deaths worldwide. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market.\n<\/p>\n<p>\nStringent regulations imposed on the approval of biosimilar are anticipated to hinder the growth of oral biologics and the biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars.\n<\/p>\n<p>\nFurther, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics.\n<\/p>\n<p>\nIn February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar markets.\n<\/p>\n<p>\nThe creation of new insulin biosimilar is a key trend gaining popularity in the oral biologics and biosimilar market. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance, in 2019, Mylan, a US-based pharmaceuticals company, in partnership with Biocon launched a biosimilar insulin glargine named Semglee in Australia.\n<\/p>\n<p>\n<strong>Scope<\/strong>\n<\/p>\n<p>\n<strong>Markets Covered:<\/strong>\n<\/p>\n<p>\n1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors\n<\/p>\n<p>\n2) By Disease: Asthma, Crohn&#8217;s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others\n<\/p>\n<p>\n3) By Molecule Type: Vaccines, Proteins &amp; Peptides, Monoclonal Antibodies, Others\n<\/p>\n<p>\n4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies\n<\/p>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>2. Oral Biologics &amp; Biosimilars Market Characteristics<\/strong>\n<\/p>\n<p>\n<strong>3. Oral Biologics &amp; Biosimilars Market Trends And Strategies<\/strong>\n<\/p>\n<p>\n<strong>4. Impact Of COVID-19 On Oral Biologics &amp; Biosimilars<\/strong>\n<\/p>\n<p>\n<strong>5. Oral Biologics &amp; Biosimilars Market Size And Growth<\/strong>\n<\/p>\n<p>\n<strong>6. Oral Biologics &amp; Biosimilars Market Segmentation<\/strong>\n<\/p>\n<p>\n<strong>7. Oral Biologics &amp; Biosimilars Market Regional And Country Analysis<\/strong>\n<\/p>\n<p>\n<strong>8. Asia-Pacific Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>9. China Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>10. India Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>11. Japan Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>12. Australia Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>13. Indonesia Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>14. South Korea Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>15. Western Europe Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>16. UK Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>17. Germany Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>18. France Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>19. Eastern Europe Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>20. Russia Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>21. North America Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>22. USA Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>23. South America Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>24. Brazil Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>25. Middle East Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>26. Africa Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>27. Oral Biologics &amp; Biosimilars Market Competitive Landscape And Company Profiles<\/strong>\n<\/p>\n<p>\n<strong>28. Oral Biologics &amp; Biosimilars Pipeline Analysis<\/strong>\n<\/p>\n<p>\n<strong>29. Key Mergers And Acquisitions In The Oral Biologics &amp; Biosimilars Market<\/strong>\n<\/p>\n<p>\n<strong>30. Oral Biologics &amp; Biosimilars Market Future Outlook and Potential Analysis<\/strong>\n<\/p>\n<p>\n<strong>31. Appendix<\/strong>\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nNovartis\n<\/li>\n<li>\nRani Therapeutics\n<\/li>\n<li>\nEli Lilly and Co\n<\/li>\n<li>\nAstraZeneca plc\n<\/li>\n<li>\nNovo Nordisk A\/S\n<\/li>\n<li>\nBiocon Limited\n<\/li>\n<li>\nOramed Pharmaceuticals\n<\/li>\n<li>\nBiosanaPharma\n<\/li>\n<li>\nEntera Bio Ltd.\n<\/li>\n<li>\nAllergan plc\n<\/li>\n<li>\nEmisphere Technologies\n<\/li>\n<li>\nEnteris BioPharma\n<\/li>\n<li>\nChiasma\n<\/li>\n<li>\nAllena Pharmaceuticals\n<\/li>\n<li>\nGelgen\n<\/li>\n<li>\nGanlee\n<\/li>\n<li>\n3sbio\n<\/li>\n<li>\nInnovent\n<\/li>\n<li>\nRetractable Technologies, Inc.\n<\/li>\n<li>\nChangchun High Tech\n<\/li>\n<li>\nDong Bao\n<\/li>\n<li>\nCP Guojian\n<\/li>\n<li>\nGlaxoSmithKline Plc\n<\/li>\n<li>\nConcord Biotech\n<\/li>\n<li>\nAurobindo Pharma Ltd.\n<\/li>\n<li>\nH. Lundbeck A\/S\n<\/li>\n<li>\nSanofi-Aventis\n<\/li>\n<li>\nRoche.\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5656272\/oral-biologics-and-biosimilars-global-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=nbptq4&amp;utm_campaign=1758645+-+Oral+Biologics+%26+Biosimilars+Global+Market+Report+2022%3A+Rising+Prevalence+of+Chronic+Diseases+Such+as+Arthritis%2C+Asthma%2C+and+Cancer+Driving+Growth&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/4xc7t6<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;:pr&#x65;&#x73;&#x73;&#x40;&#114;&#101;sea&#x72;&#x63;&#x68;&#x61;&#110;&#100;&#109;ar&#x6b;&#x65;&#x74;&#x73;&#46;&#99;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#x65;&#115;&#x73;&#x40;&#114;&#x65;&#x73;&#101;&#x61;&#x72;&#99;&#x68;&#x61;&#110;&#x64;&#x6d;&#97;&#x72;&#x6b;&#101;&#x74;&#x73;&#46;&#x63;&#x6f;m<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Oral Biologics &amp; Biosimilars Global Market Report 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global oral biologics &amp; biosimilars market is expected to grow from $4.24 billion in 2021 to $5.24 billion in 2022 at a compound annual growth rate (CAGR) of 23.4%. The oral biologics &amp; biosimilars market is expected &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49214","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Oral Biologics &amp; Biosimilars Global Market Report 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global oral biologics &amp; biosimilars market is expected to grow from $4.24 billion in 2021 to $5.24 billion in 2022 at a compound annual growth rate (CAGR) of 23.4%. The oral biologics &amp; biosimilars market is expected ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T19:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-10-05T19:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/\"},\"wordCount\":844,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005723\\\/en\\\/1593244\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/\",\"name\":\"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005723\\\/en\\\/1593244\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-10-05T19:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005723\\\/en\\\/1593244\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005723\\\/en\\\/1593244\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Oral Biologics &amp; Biosimilars Global Market Report 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global oral biologics &amp; biosimilars market is expected to grow from $4.24 billion in 2021 to $5.24 billion in 2022 at a compound annual growth rate (CAGR) of 23.4%. The oral biologics &amp; biosimilars market is expected ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-05T19:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth &#8211; ResearchAndMarkets.com","datePublished":"2022-10-05T19:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/"},"wordCount":844,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/","name":"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg","datePublished":"2022-10-05T19:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221005005723\/en\/1593244\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/oral-biologics-biosimilars-global-market-report-2022-rising-prevalence-of-chronic-diseases-such-as-arthritis-asthma-and-cancer-driving-growth-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Oral Biologics &amp; Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49214"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49214\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}